热门资讯> 正文
Zynex获得FDA批准推出新疼痛管理设备
2024-09-03 22:08
- MedTech company Zynex (NASDAQ:ZYXI) on Tuesday announced FDA clearance for its new pain management device, TensWave.
- The product is a prescription-only medical device designed to reduce chronic and acute pain without medication. TensWave provides pain relief using TENS (Transcutaneous Electrical Nerve Stimulation) therapy.
- It complements Zynex's (ZYXI) flagship pain management device, NexWave, which uses interferential current (IC) as the main modality.
- The company said TensWave suits patients whose insurance plans exclusively cover TENS therapy.
- "We recognized a gap in the market for a high-quality TENS device that meets the specific criteria for insurance reimbursement, and TensWave is our answer to that demand," said Thomas Sandgaard, CEO of Zynex Medical.
- "The introduction of TensWave aligns perfectly with our commitment to providing comprehensive pain management solutions," he added.
More on Zynex
- Zynex, Inc. (ZYXI) Q2 2024 Earnings Call Transcript
- Zynex GAAP EPS of $0.04 misses by $0.04, revenue of $49.88M misses by $2.21M
- Seeking Alpha’s Quant Rating on Zynex
- Historical earnings data for Zynex
- Financial information for Zynex
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
